Your browser doesn't support javascript.
loading
Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma.
Suzuki, Kenshi; Sunami, Kazutaka; Matsumoto, Morio; Maki, Akio; Shimada, Fumika; Suzuki, Kazuyuki; Shimizu, Kazuyuki.
Affiliation
  • Suzuki K; Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan, ken-suzuki@mtb.biglobe.ne.jp.
  • Sunami K; Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.
  • Matsumoto M; Department of Hematology, National Hospital Organization Shibukawa Medical Center, Shibukawa, Japan.
  • Maki A; Novartis Pharma K.K., Tokyo, Japan.
  • Shimada F; Novartis Pharma K.K., Tokyo, Japan.
  • Suzuki K; Novartis Pharma K.K., Tokyo, Japan.
  • Shimizu K; Department of Hematology/Oncology, Higashi Nagoya National Hospital, Nagoya, Japan.
Acta Haematol ; 144(3): 264-274, 2021.
Article in En | MEDLINE | ID: mdl-33279887
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dexamethasone / Antineoplastic Combined Chemotherapy Protocols / Bortezomib / Panobinostat / Multiple Myeloma Type of study: Clinical_trials / Etiology_studies / Guideline Limits: Adult / Aged / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Acta Haematol Year: 2021 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dexamethasone / Antineoplastic Combined Chemotherapy Protocols / Bortezomib / Panobinostat / Multiple Myeloma Type of study: Clinical_trials / Etiology_studies / Guideline Limits: Adult / Aged / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Acta Haematol Year: 2021 Type: Article